MRNA vs QGEN
Moderna, Inc. and Qiagen N.v., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MRNA | QGEN |
|---|---|---|
| Revenue | $1.9B | $2.1B |
| Net income | $-2.8B | $424.9M |
| Gross margin | 55.3% | 62.2% |
| Net margin | −145.2% | 20.3% |
| Return on equity | −28.9% | 11.6% |
| Diluted EPS | −$7.26 | $1.94 |
| Dividend / share | · | $0.25 |
| Payout ratio | · | 12.8% |
| Free cash flow | $-2.1B | $453.3M |
| Equity | $8.7B | $3.8B |
| Net debt / equity | −0.23× | 0.22× |
| Current ratio | 3.29× | 3.90× |
| Revenue CAGR 5y | 19.3% | 2.2% |
| Profit CAGR 5y | · | 3.4% |
MRNA and QGEN book revenue within 15% of each other, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | MRNA | QGEN |
|---|---|---|
| FY2025 | $1.9B | $2.1B |
| FY2024 | $3.2B | $2.0B |
| FY2023 | $6.8B | $2.0B |
| FY2022 | $19.3B | $2.1B |
| FY2021 | $18.5B | $2.3B |
| FY2020 | $803.0M | $1.9B |
| FY2019 | $60.0M | $1.5B |
| FY2018 | $135.1M | $1.5B |
| FY2017 | $205.8M | $1.4B |
| FY2016 | $108.4M | $1.3B |
Bottom line
| Fiscal year | MRNA | QGEN |
|---|---|---|
| FY2025 | $-2.8B | $424.9M |
| FY2024 | $-3.6B | $83.6M |
| FY2023 | $-4.7B | $341.3M |
| FY2022 | $8.4B | $423.2M |
| FY2021 | $12.2B | $512.6M |
| FY2020 | $-747.0M | $359.2M |
| FY2019 | $-514.0M | $-41.5M |
| FY2018 | $-384.7M | $190.4M |
| FY2017 | $-255.9M | $40.4M |
| FY2016 | $-216.2M | $80.4M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$145,999,000 | QGEN |
| FY2024 | +$1,257,786,000 | MRNA |
| FY2023 | +$4,882,689,000 | MRNA |
| FY2022 | +$17,121,482,000 | MRNA |
| FY2021 | +$16,219,343,000 | MRNA |
| FY2020 | −$1,067,346,000 | QGEN |
| FY2019 | −$1,466,424,000 | QGEN |
| FY2018 | −$1,366,780,000 | QGEN |
| FY2017 | −$1,211,711,000 | QGEN |
| FY2016 | −$1,229,595,000 | QGEN |
The higher-revenue side has changed between MRNA and QGEN over this period. The gap has narrowed since the earliest year compared.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −165.5 pp | QGEN |
| FY2024 | −114.3 pp | QGEN |
| FY2023 | −86.2 pp | QGEN |
| FY2022 | +23.6 pp | MRNA |
| FY2020 | −112.2 pp | QGEN |
| FY2019 | −854.0 pp | QGEN |
| FY2018 | −297.5 pp | QGEN |
| FY2017 | −127.2 pp | QGEN |
| FY2016 | −205.5 pp | QGEN |
The higher net margin has changed hands between MRNA and QGEN over this period.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's net margin has been more volatile than QGEN's over the 9 comparable fiscal years — 245.6 percentage points of standard deviation against 8.2.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between MRNA and QGEN over these 9 fiscal years — MRNA led in 1 and QGEN in 8.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's return on equity has been more volatile than QGEN's over the 7 comparable fiscal years — 64.6 percentage points of standard deviation against 6.2.
7 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between MRNA and QGEN over these 7 fiscal years — MRNA led in 2 and QGEN in 5.
7 of 18 comparable fiscal years — a year missing data on either side is not counted.